Is it the blood pressure or the blood vessel?

被引:13
作者
Cohn, Jay N. [1 ]
机构
[1] Univ Minnesota, Sch Med, Div Cardiovasc, Minneapolis, MN 55455 USA
关键词
Blood pressure; vascular resistance; endothelial dysfunction; vascular structure; antihypertensive drugs; morbid events;
D O I
10.1016/j.jash.2006.11.001
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
The physiologic link between vascular health and arterial pressure makes it difficult to separate the adverse effects of pressure and vascular functional and structural alterations in determining the adverse complications of hypertension. Since endothelial dysfunction and nitric oxide deficiency are characteristic features of hypertension and of other risk factors for morbid events, it is proposed that blood pressure elevation may be viewed in part as a complication of functional and structural changes in the microcirculation, and that structural changes in the conduit arteries leading to morbid events may be viewed as a complication of both pressure elevation and endothelial dysfunction. Improvement in endothelial dysfunction will relax the microcirculation and lower blood pressure. Thus pressure elevation and its lowering in resposne to treatment serves as a useful guide to the vascular abnormality and its amelioration, but vascular structural abnormalities are the proximate cause of vascular events and therapy aimed at the vasculature rather than the pressure may serve as a more sensitive and specific guide to treatment. (c) 2007 American Society of Hypertension. All rights reserved.
引用
收藏
页码:5 / 16
页数:12
相关论文
共 71 条
[31]  
Hjalmarson Å, 1999, LANCET, V353, P2001
[32]   Feasibility of treating prehypertension with an angiotensin-receptor blocker [J].
Julius, S ;
Nesbitt, SD ;
Egan, BM ;
Weber, MA ;
Michelson, EL ;
Kaciroti, N ;
Black, HR ;
Grimm, RH ;
Messerli, FH ;
Oparil, S ;
Schork, MA .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (16) :1685-1697
[33]   Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial [J].
Julius, S ;
Kjeldsen, SE ;
Weber, M ;
Brunner, HR ;
Ekman, S ;
Hansson, L ;
Hua, TS ;
Laragh, J ;
McInnes, GT ;
Mitchell, L ;
Plat, F ;
Schork, A ;
Smith, B ;
Zanchetti, A .
LANCET, 2004, 363 (9426) :2022-2031
[34]   Blood pressure as a cardiovascular risk factor - Prevention and treatment [J].
Kannel, WB .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 275 (20) :1571-1576
[35]  
KIKKAWA R, 1992, J AM SOC NEPHROL, V3, pS120
[36]   Arterial and cardiac aging: Major shareholders in cardiovascular disease enterprises Part I: Aging arteries: A "set up" for vascular disease [J].
Lakatta, EG ;
Levy, D .
CIRCULATION, 2003, 107 (01) :139-146
[37]  
Lechat P, 1999, LANCET, V353, P9
[38]   Meta-analysis: Angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction [J].
Lee, VC ;
Rhew, DC ;
Dylan, M ;
Badamgarav, E ;
Braunstein, GD ;
Weingarten, SR .
ANNALS OF INTERNAL MEDICINE, 2004, 141 (09) :693-704
[39]   Treatment with amlodipine and atorvastatin have additive effect in improvement of arterial compliance in hypertensive hyperlipidemic patients [J].
Leibovitz, E ;
Beniashvili, M ;
Zimlichman, R ;
Freiman, A ;
Shargorodsky, M ;
Gavish, D .
AMERICAN JOURNAL OF HYPERTENSION, 2003, 16 (09) :715-718
[40]  
Lewington S, 2002, LANCET, V360, P1903, DOI 10.1016/S0140-6736(02)11911-8